

Angew Chem Int Ea Engl. Author manuscript; available in PMC 2013 December 14

Published in final edited form as:

Angew Chem Int Ed Engl. 2012 December 14; 51(51): 12846–12849. doi:10.1002/anie.201207949.

Total Synthesis of the Unusual Monoterpenoid Indole Alkaloid (±)-Alstilobanine A**

Yiqing Feng, Max M. Majireck, and Prof. Dr Steven M. Weinreb*

Department of Chemistry The Pennsylvania State University University Park, Pennsylvania, 16802 USA

Keywords

alkaloids; nitrogen heterocycles; total synthesis; nitrosoalkene conjugate addition; -lactone

The monoterpene indole alkaloids, which are usually comprised of a tryptamine moiety appended to a single C9- or C10-terpenoid unit, constitute one of the largest known classes of natural products. [1] In 2004, Kam and Choo isolated a new type of monoterpenoid indole alkaloid, angustilodine (1), which contains a unique rearranged skeleton, from the leaves of the Malayan plant Alstonia angustiloba (Figure 1). [2] The structure of angustilodine was determined by detailed spectroscopic analysis to include an indole appended to a *cis*-fused 2-azadecalin ring system bearing a 7-membered ring ether bridge. An interesting conformational feature of this molecule established by 2D NMR studies is the observation that the piperidine ring exists as a boat. More recently, Morita and coworkers discovered the N-demethyl congener alstilobanine E (2), along with alstilobanine A (3), which lacks the bridging oxepane ring found in 1 and 2, in the same plant. [3] Unlike alkaloids 1 and 2, it was proposed that alstilobanine A has the piperidine ring in a chair conformation as shown in Figure 1. Alstilobanines A and E were found to possess modest relaxant activity against phenylephrine-induced contractions of thoracic rat aortic rings with endothelium. In this communication we describe the first approach to these alkaloids, culminating in a convergent total synthesis of racemic alstilobanine A (3).

Our synthetic strategy was predicated upon effecting two key carbon-carbon single bond constructions. The first planned transformation involved an intermolecular conjugate addition of an indole ester enolate to a 3-piperidone-derived nitrosoalkene to form the C-15,16 bond of the alkaloid.^[4] The second pivotal step was to apply the methodology of Romo, et al. for intramolecular -lactone formation^[5] to generate the requisite *cis*-2-azadecalin moiety via C-19,20 bond formation, along with the necessary functionality and three contiguous stereocenters at C-15,19,20. The implementation of this strategy is outlined here.^[6]

Thus, indole 2-acetic acid methyl ester (4)^[7] was first acylated at C-3 with oxalyl chloride, followed by *in situ* treatment of the resulting -keto acid chloride with 2-trimethylsilylethanol to afford keto diester 5 (Scheme 1). In order to generate the C-15,16 bond of 3, indole ester 5 was first converted to the dianion 6 using two equivalents of lithium hexamethyldisilazide. Addition of one equivalent of the -chlorooxime 7 derived

^{**}We are grateful to the National Institutes of Health (GM-087733) and the National Science Foundation (CHE-1105653) for financial support of this research.

^{*}Fax: 814-865-3292 smw@chem.psu.edu.

from *N*-tosyl-3-piperidone^[8] to the dianion led to the desired coupled product as a 1.2:1 mixture of diastereomers **11a** and **11b** which could be separated for characterization, each as a single oxime *E*-geometric isomer, in high total yield. It should be noted that the C-16 mixture obtained in the conjugate addition reaction is of no consequence since it is subsequently corrected (*vide infra*).

We believe that this novel transformation involves the initial dehydrohalogenation of - chlorooxime **7** by dianion **6** to generate a transient nitrosoalkene **10** along with a monoanion derived from the indole ester. It seems likely that this intermediate is probably an equilibrium mixture of resonance stabilized anions **8** and **9**, but the conjugate addition to nitrosoalkene **10** occurs exclusively via the latter form.

To continue the synthesis, the oxime moiety of the mixture of indole ester adducts **11a** and **11b** was first protected as the TBS ether **12** (Scheme 2). At this stage, the -ketoester **12** was deoxygenated via a modification of the method of Hlasta, et al. ^[9] Thus, the ketone was first reduced to the alcohol which was then converted to the corresponding acetate, followed by catalytic hydrogenation using Pd/C in *t*-butanol/triethylamine to afford a mixture of diastereomeric diesters **13** and **14** which were easily separated by column chromatography. ^[10]

Since it was later found that these two diastereomeric C-15/16 systems behave differently during the key Romo cyclization (*vide infra*), isomer **13** was epimerized cleanly to **14** in 70% isolated yield by treatment with potassium hexamethyldisilazide, followed by quenching with aqueous ammonium chloride. The indole nitrogen of **14** was then protected with a Cbz group to afford derivative **15** whose structure was established by X-ray analysis, confirming both the C-15/16 relative stereochemistry and the *O*-silyloxime *E*-geometry. [11] At this point, *O*-silyloxime **15** was converted to oxime **16** with TBAF, followed by acidic cleavage to give the corresponding ketone **17**. [12]

Initial attempts to convert the trimethylsilylethyl ester **17** to the corresponding carboxylic acid with fluoride sources failed,^[6] but this transformation could be performed with trifluoroacetic acid in methylene chloride to afford the desired keto acid **18** in high yield without affecting the methyl ester (Scheme 3).^[13] With compound **18** in hand, we were prepared to attempt the second key step, a Romo formal ketene/ketone-[2+2]-intramolecular cycloaddition to generate the requisite fused -lactone *cis*-2-azadecalin system.

Therefore, treatment of the keto acid **18** with 2-bromo-*N*-propylpyridinium triflate, 4-pyrrolidinopyridine (PPY) and Hunig's base in CH₂Cl₂ containing 1.2 equivalents of acetic acid to avoid epimerization of the C-16 ester led to the desired fused -lactone system **19** needed for alstilobanine A along with a trace of the *trans*-2-azadecalin **21** (97:3 NMR ratio) in high yield. [5b] Interestingly, when the Romo cyclization was conducted on the C-16 ester epimer of keto acid **18** prepared from intermediate **13**, the major product was the undesired *trans*-2-azadecalin.

With key intermediate **19** now in hand, we began to investigate introduction of a hydroxymethyl group at C-16. Since we had found in earlier work with various other intermediates that it was not possible to generate a C-16 ester enolate if a Cbz protecting group is in place on the indole nitrogen,^[6,14] this group was removed from **19** via hydrogenolysis to afford NH-indole ester **20**. This compound could be successfully deprotonated with two equivalents of lithium hexamethyldisilazide to generate the dianion **22**, followed by alkylation with monomeric formaldehyde^[15] from the least hindered face to produce -hydroxymethyl ester **23** as a single diastereomer having the configuration needed for alkaloid **3** (Scheme 4).^[16] The stereochemistry of compound **23** was established by 2D

NMR analysis and was also confirmed by the fact that the -lactone underwent acyl migration to afford the bridged seven-membered lactone **24** upon treatment with triethylamine in methylene chloride.

Since it was observed that the hydroxymethyl group of **23** tends to be lost under a variety of conditions via a retro-aldol process, this functionality was protected as the TBS ether **25** (Scheme 5). The -lactone moiety of **25** could then be reduced selectively with LiBH₄ in THF to yield the diol ester **26**, that was converted to iodo alcohol **27** via an Appel reaction. Subsequent catalytic hydrogenation of this compound at atmospheric pressure using 10% Pd/C in a 1:1 mixture of ethyl acetate: *t*-butanol cleanly led to the desired methyl compound **28**. The *N*-tosyl protecting group of intermediate **28** was cleaved using magnesium metal turnings in methanol under sonication to afford piperidine **29** in good yield. Once, again the structure and stereochemistry of this intermediate were confirmed by 2D NMR analysis (see Supporting Information). Finally, removal of the TBS protecting group with HCl in methanol/chloroform afforded racemic alstilobanine A (**3**), isolated as its hydrochloride salt, having proton and carbon NMR spectra as reported for the natural alkaloid. A (**3**)

In summary, we have devised a convergent approach to a total synthesis of the novel indole alkaloid alstilobanine A (3). The synthesis of 3 requires about twenty operations starting from indole methyl ester 4. Key steps in the route include an unprecedented conjugate addition of an indole acetate ester enolate to a nitrosoalkene, and an intramolecular Romo cyclization to generate a -lactone fused to the requisite *cis*-2-azadecalin needed for the alkaloid. Work is currently underway using the intermediates described here for construction of the bridging oxepane ring directed towards syntheses of the congeneric alkaloids 1 and 2.^[20]

Supplementary Material


Refer to Web version on PubMed Central for supplementary material.

References

- [1] (a). For reviews see: Cordell GA. Introduction to Alkaloids: A Biogenetic Approach. 1981Wiley-InterscienceNew York Pelletier SW. Pelletier SW. Alkaloids: Chemical and Biological Perspectives. 1983; Vol. 1WileyNew York Bisset NG. Phillipson JD, Zenk MH. Indoles and Biogenetically Related Alkaloids. 1980Academic PressLondon Herbert RB. Saxton JE. The Chemistry of Heterocyclic Compounds. Indoles Part 4, The Monoterpenoid Indole Alkaloids. 1983WileyNew York Atta-ur-Rahman, A. Basha Biosynthesis of Indole Alkaloids. 1983Clarendon PressOxford Kutchan TM. Phytochemistry. 1993; 32:493. [PubMed: 7763429]
- [2]. Kam T-S, Choo Y-M. Helv. Chim. Acta. 2004; 87:366.
- [3]. Koyama K, Hirasawa Y, Zaima K, Hoe TC, Chan K-L, Morita H. Bioorg. Med. Chem. 2008; 16:6483. [PubMed: 18524603]
- [4] (a). For reviews of nitrosoalkenes see: Gilchrist TL. Chem. Soc. Rev. 1983; 12:53. Lyapkalo IM, Ioffe SL. Russ. Chem. Rev. 1998; 67:467.
- [5] (a). Oh SH, Cortez GS, Romo D, Org J. Chem. 2005; 70:2835.(b) Henry-Riyad H, Lee C, Purohit VC, Romo D. Org. Lett. 2006; 8:4363. [PubMed: 16956227] (c) Ma G, Nguyen H, Romo D. Org. Lett. 2007; 9:2143. [PubMed: 17477539] (d) Purohit VC, Matla AS, Romo D. J. Am. Chem. Soc. 2008; 130:10478. [PubMed: 18627148] (e) Nguyen H, Ma G, Romo D. Chem. Commun. 2010; 46:4803.(f) Morris KA, Arendt KM, Oh SH, Romo D. Org. Lett. 2010; 12:3764. [PubMed: 20704184] (g) Nguyen H, Ma G, Gladysheva T, Fremgen T, Romo D. J. Org. Chem. 2011; 76:2. [PubMed: 21047113]
- [6]. Taken in part from: Majireck MM. Ph.D. Thesis, The Pennsylvania State University. 2011
- [7]. Mahboobi S, Bernauer K. Helv. Chim. Acta. 1988; 71:2034.

- [8]. Chauhan PS, Majireck MM, Weinreb SM. Heterocycles. 2012; 84:577.
- [9]. Hlasta DJ, Luttinger D, Perrone MH, Silbernagel MJ, Ward SJ, Haubrich DR. J. Med. Chem. 1987; 30:1555. [PubMed: 2887657]

[10]. This transformation presumably occurs via an azafulvene intermediate **i** derived from the indole. Evidence for this supposition is that if the hydrogenation is conducted in ethanol rather than *t*-butanol, a significant amount of product **ii** results where the acetate group is replaced by ethoxyl via interception of azafulvene **i** by the solvent. This compound is resistant to further catalytic reduction. ^[6]



- [11]. We thank Dr. Hemant Yennawar (Penn State Small Molecule X-Ray Crystallographic Facility) for the crystal structure determination.
- [12]. DePuy CH, Ponder BW. J. Am. Chem. Soc. 1959; 81:4629.
- [13]. Van den Broek LAGM, Breuer ML, Liskamp RMJ, Ottenheijm HCJ. J. Org. Chem. 1987; 52:1511.
- [14]. We believe the bulky **N**-Cbz group causes the adjacent ester to assume a conformation which is not favorably disposed stereoelectronically for -proton removal by base.
- [15]. Schlosser M, Jenny T, Guggisberg Y. Synlett. 1990; 11:704.
- [16]. Martin, Cf. C. L.; Overman, LE.; Rohde, JM. J. Am. Chem. Soc. 2010; 132:4894. [PubMed: 20218696]
- [17]. See for example: Huscroft IT, Carlson EJ, Chicchi GG, Kurtz MM, London C, Raubo P, Wheeldon A, Kulagowski JJ. Bioorg. Med. Chem. Lett. 2006; 16:2008. [PubMed: 16413782]
- [18]. Nyasse B, Grehn L, Ragnarsson U. Chem. Commun. 1997:1017.
- [19]. We are grateful to Professor H. Morita (Hoshi University) for copies of the NMR spectra of the TFA salt of the natural alkaloid.
- [20]. Although alkaloids 1 and 2 in principle could be prepared via removal of the lactone oxygen of intermediate 24, to date we have been unable to execute this transformation. Researchis continuing on solving this problem and/or finding another approach to angustilodine and alstilobanine E.

$$\begin{array}{c} OH \\ N \\ H \\ CO_2Me \end{array} = \begin{array}{c} OH \\ N \\ H \\ CO_2Me \end{array} = \begin{array}{c} OH \\ N \\ R \\ R \end{array}$$

1 R = Me angustilodine 2 R = H alstilobanine E

3 alstilobanine A

Figure 1. Structures of the alstilobanine alkaloids.

Scheme 1. Nitrosoalkene conjugate addition.

Scheme 2. Preparation of Intermediate **17**

Scheme 3.
Romo cyclization of keto acid 18 to pentacyclic -lactone 19

Scheme 4. Stereoselective C-16 hydroxymethylation

Scheme 5. Completion of the synthesis of (±) alstilobanine A (3).